Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection

Detalles Bibliográficos
Autores principales: Youssef, Soundos, Lavian, Jonathan, Lee, Eunice Y., Fan, Weijia, Bordone, Lindsey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: by the American Academy of Dermatology, Inc. 2023
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085348/
https://www.ncbi.nlm.nih.gov/pubmed/35551958
http://dx.doi.org/10.1016/j.jaad.2022.05.005
_version_ 1784703795617333248
author Youssef, Soundos
Lavian, Jonathan
Lee, Eunice Y.
Fan, Weijia
Bordone, Lindsey A.
author_facet Youssef, Soundos
Lavian, Jonathan
Lee, Eunice Y.
Fan, Weijia
Bordone, Lindsey A.
author_sort Youssef, Soundos
collection PubMed
description
format Online
Article
Text
id pubmed-9085348
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher by the American Academy of Dermatology, Inc.
record_format MEDLINE/PubMed
spelling pubmed-90853482022-05-10 Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection Youssef, Soundos Lavian, Jonathan Lee, Eunice Y. Fan, Weijia Bordone, Lindsey A. J Am Acad Dermatol Research Letter by the American Academy of Dermatology, Inc. 2023-05 2022-05-10 /pmc/articles/PMC9085348/ /pubmed/35551958 http://dx.doi.org/10.1016/j.jaad.2022.05.005 Text en © 2022 by the American Academy of Dermatology, Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Research Letter
Youssef, Soundos
Lavian, Jonathan
Lee, Eunice Y.
Fan, Weijia
Bordone, Lindsey A.
Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection
title Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection
title_full Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection
title_fullStr Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection
title_full_unstemmed Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection
title_short Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection
title_sort tofacitinib therapy for alopecia areata is not associated with adverse events during covid-19 infection
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085348/
https://www.ncbi.nlm.nih.gov/pubmed/35551958
http://dx.doi.org/10.1016/j.jaad.2022.05.005
work_keys_str_mv AT youssefsoundos tofacitinibtherapyforalopeciaareataisnotassociatedwithadverseeventsduringcovid19infection
AT lavianjonathan tofacitinibtherapyforalopeciaareataisnotassociatedwithadverseeventsduringcovid19infection
AT leeeunicey tofacitinibtherapyforalopeciaareataisnotassociatedwithadverseeventsduringcovid19infection
AT fanweijia tofacitinibtherapyforalopeciaareataisnotassociatedwithadverseeventsduringcovid19infection
AT bordonelindseya tofacitinibtherapyforalopeciaareataisnotassociatedwithadverseeventsduringcovid19infection

Ejemplares similares